Semaglutide and menopause can fit into the same care plan when weight management is medically appropriate. Studies have found weight loss after menopause, including among women who were not using hormone therapy. Semaglutide does not replace estrogen or provide an established treatment for hot flashes.
The useful question is what is changing: weight, waist size, sleep, strength, or menopause symptoms. Those problems can overlap, but each needs its own explanation.
Why weight and shape change around menopause
Menopause means periods have stopped for at least 12 months, without another explanation. Perimenopause is the transition before that point. Estrogen, a hormone involved in reproductive and bone health, falls during this transition.
Weight and body shape do not always change together. In SWAN, a long-running study of women across menopause, fat gain accelerated while lean tissue began declining around the transition. Lean tissue is tissue other than fat and bone, including muscle, organs, and body water. A scan does not measure muscle alone. The rate of weight gain did not accelerate at the same point (Greendale et al., JCI Insight, 2019).
That helps explain why clothes can fit differently without a dramatic change on the scale. The waistline deserves attention, but so do strength and overall health.
What studies say about semaglutide and menopause
Semaglutide acts like GLP-1, a gut hormone that helps regulate appetite and blood sugar. Its weight-management evidence comes from studies of specific manufactured products, doses, and populations.
As of September 30, 2026, the day this article was written, a STEP and OASIS analysis presented November 4–7, 2025 reported weight reductions before, during, and after menopause. Researchers regrouped existing trial data, a method called a post hoc analysis. The conference presentation, involving the manufacturer, included only women with measurements available at the start and end.
That supports the possibility of weight loss across stages. It cannot promise identical results at every age. The STEP 1 trial explainer covers the original study's wider results and limits.
Semaglutide and HRT: what the Mayo study found
Menopause hormone therapy, often called HRT, replaces hormones to address specific menopause-related needs. A 2024 Mayo Clinic study looked back at medical records, making it retrospective rather than a trial assigning hormone treatment by chance.
The study initially included 106 postmenopausal women receiving semaglutide for overweight or obesity. Sixteen used hormone therapy; 90 did not. At 12 months, average weight reduction was 16% versus 12% (Hurtado et al., Menopause, 2024).
The groups differed in other ways, and hormone treatment had already begun before semaglutide. The researchers accounted for measured differences between groups, but that does not establish that hormones caused the extra loss.
As of September 30, 2026, the day this article was written, a Spanish Menopause Society statement published online August 25, 2026 advises against starting hormone therapy solely to increase semaglutide-related weight loss. It describes the direct menopause evidence as limited and largely observational, meaning it mostly follows existing treatment choices.
Existing HRT use belongs in the medication review. Hormone treatment has its own reasons, risks, and follow-up needs.
Where tirzepatide fits in menopause care
Tirzepatide is another medicine a clinician may consider for weight management. It acts on GLP-1 and GIP, a second gut-hormone signal involved in blood-sugar regulation. That different mechanism does not establish which medicine suits one person.
The tirzepatide and menopause guide covers its separate evidence, including hormone-therapy research. Neither medicine replaces a menopause assessment. Choice also depends on medical history, side effects, and whether adequate nutrition remains manageable as appetite falls.
Muscle and bone deserve more than a passing mention
Weight loss includes more than fat. After menopause, that makes food intake, strength, falls, and fracture history part of the conversation. The semaglutide and muscle-loss guide explains why a drop in measured lean tissue is not the same as an equal drop in muscle.
Bone evidence deserves care too. A 52-week Danish trial enrolled 64 adults at increased fracture risk, including 55 postmenopausal women. With semaglutide 1.0 mg weekly, bone density, a measure of mineral in bone, was lower at the spine and hip than with placebo, an inactive comparison injection (Hansen et al., eClinicalMedicine, 2024). That small trial did not establish fracture risk for every woman using semaglutide.
As of September 30, 2026, the day this article was written, the Wegovy label marked “Revised: 6/2026” reports hip and pelvis fractures in 1% of women receiving Wegovy versus 0.2% receiving placebo in its heart-outcomes trial. Those were women with existing cardiovascular disease, meaning disease of the heart or blood vessels. The figures are not a menopause-specific risk estimate.
A clinician can consider nutrition, resistance exercise that challenges muscles against weight, and existing osteoporosis, a condition that makes bones fragile. Progress includes everyday function, not just pounds lost.
Bleeding after menopause needs its own assessment
As of September 30, 2026, the day this article was written, a September 16, 2026 case report in JCEM Case Reports describes vaginal bleeding after semaglutide was started. The bleeding ended after treatment stopped. One case cannot establish how often this happens or prove a general cause.
New bleeding after menopause warrants assessment for other causes, including cancer, before anyone attributes it to medication. It is not evidence that normal periods or fertility have returned. The prescriber and gynecologist decide what the symptoms mean and whether treatment changes are appropriate.
What a provider considers before prescribing
Menopause alone does not establish a reason for semaglutide. A provider considers weight history, related health conditions, current medicines, digestive problems, and the standard safety screen. Pancreatitis, inflammation of the pancreas, belongs in that history. The label rules out use with a personal or family history of medullary thyroid cancer, a rare thyroid cancer.
Perimenopause also does not rule out pregnancy. For weight management, the Wegovy label specifies discontinuation at least two months before a planned pregnancy. The semaglutide and pregnancy guide explains that separate planning question. The prescriber sets the actual dose and pace; persistent nausea or difficulty eating enough may change the plan.
Where compounded semaglutide fits
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.
As of September 30, 2026, the day this article was written, the FDA's compounding explanation states that these preparations do not undergo its review for safety, effectiveness, or quality before marketing. The cited trials do not establish results for Promise's specific preparation.
A licensed provider may still prescribe a compounded formulation when appropriate; that decision is between the patient and the doctor. At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies.
